通过混合类型的动力学和稳定的结合在分子动力学模拟中抑制CYP1B1
Liwei Jia1, Lei Zhou1, Shujun Zou1
1School of Pharmacy, Heilongjiang University of Chinese Medicine, No.24 Heping Road, Harbin, 150040, People's Republic of China.
酸 (PA) 抑制了与癌症相关的酶细胞染色体P450 1B1 (CYP1B1). 分子模拟显示PA与CYP1B1结合,表明其作为天然抗癌剂的潜力.
科学领域:
- 生物化学
- 药理学
- 分子生物学
背景情况:
- 细胞染色体P450 1B1 (CYP1B1) 涉及致癌物激活和雌激素代谢,导致瘤的进展.
- 了解CYP1B1抑制剂对于开发新型癌症疗法至关重要.
研究的目的:
- 为了研究氨酸 (PA) 对CYP1B1的抑制作用.
- 阐明PA抑制CYP1B1的分子机制.
主要方法:
- 酶动力学测试以确定抑制的类型和强度 (IC50).
- 分子对接和200 ns分子动力学模拟以分析结合相互作用.
- 在中预测ADMET的药理动力学和安全性.
主要成果:
- 西安丁 (PA) 呈现出CYP1B1的混合类型抑制,IC50为2. 53±0. 01μM.
- 分子对接显示PA与关键的CYP1B1残留物和血辅因子结合,破坏基质结合和电子转移.
- 分子动力学模拟证实了PA- CYP1B1复合物的稳定性.
- 在中,ADMET的预测表明安全性和肠道吸收良好,但由于膜透性低,口服生物可用性有限.
结论:
- 作为一种天然的P450 1B1 (CYP1B1) 抑制剂,氨酸 (PA) 具有显著的潜力.
- 这项研究阐明了PA对CYP1B1的抑制作用的分子基础.
- 对优化PA的药物动力学特性进行进一步的研究可以提高其在癌症预防和治疗中的临床应用.
更多相关视频
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
相关概念视频
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Inhibition of Cdk Activity
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
